|
注册号: Registration number: |
ChiCTR2500108214 |
|
最近更新日期: Date of Last Refreshed on: |
2025-10-31 17:06:50 |
|
注册时间: Date of Registration: |
2025-08-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
女性癫痫患者孕期不同剂量叶酸补充降低子代不良结局的效果及安全性的双盲随机对照试验 |
|
Public title: |
Efficacy and Safety of Different Doses of Folic Acid Supplementation in Pregnant Women with Epilepsy for Preventing Adverse Offspring Outcomes: A Double-Blind Randomized Controlled Trial |
|
注册题目简写: |
女性癫痫患者孕期不同剂量叶酸补充降低子代不良结局的效果及安全性探究 |
|
English Acronym: |
A Study Exploring the Safety and Efficacy of Different Doses of Folic Acid Supplementation in Pregnant Women with Epilepsy to Reduce Adverse Offspring Outcomes |
|
研究课题的正式科学名称: |
女性癫痫患者孕期不同剂量叶酸补充降低子代不良结局的效果及安全性的双盲随机对照试验 |
|
Scientific title: |
Efficacy and Safety of Different Doses of Folic Acid Supplementation in Pregnant Women with Epilepsy for Preventing Adverse Offspring Outcomes: A Double-Blind Randomized Controlled Trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
傅宇童 |
研究负责人: |
陈蕾 |
|
Applicant: |
Yutong Fu |
Study leader: |
Chen Lei |
|
申请注册联系人电话: Applicant telephone: |
+86 152 0846 3541 |
研究负责人电话:
Study leader's |
+86 28 8542 2007 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fuyutongscu@foxmail.com |
研究负责人电子邮件: Study leader's E-mail: |
leilei_25@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区国学巷37号 |
研究负责人通讯地址: |
四川省成都市武侯区国学巷37号 |
|
Applicant address: |
West China Hospital, Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China |
Study leader's address: |
#37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital of Sichuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025年审(1587)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Committee on Biomedical Research West China Hospital of Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-13 00:00:00 | ||
|
伦理委员会联系人: |
李娜 |
||
|
Contact Name of the ethic committee: |
Lina |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
#37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8542 2654 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
188974152@qq.com |
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital of Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
#37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
人工智能重大科技专项 |
||||||||||||||||||||||
|
Source(s) of funding: |
Major Scientific and Technological Project on Artificial Intelligence |
||||||||||||||||||||||
|
研究疾病: |
癫痫 |
||||||||||||||||||||||
|
Target disease: |
Epilepsy |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1. 主要目的:与常规补充 0.4 mg/d 叶酸相比,评价女性癫痫患者孕期强化补充 2.0mg/d叶酸降低妊娠不良事件复合终点(包括早产、小于胎龄儿、畸形、流产、死胎、神经发育异常)发生风险的效果。 2. 次要目的: 1)与常规补充 0.4 mg/d 叶酸相比,评价女性癫痫患者孕期强化补充 2.0mg/d 叶酸降低早产、小于胎龄儿、畸形、流产、死胎、神经发育异常发生风险的效果。 2)与常规补充 0.4 mg/d 叶酸相比,评价女性癫痫患者孕期强化补充 2.0mg/d 叶酸对妊娠并发症发生率的影响,妊娠并发症包括妊娠期高血压、子痫前期、胎盘早剥等。 3)与常规补充 0.4 mg/d 叶酸相比,评价女性癫痫患者孕期强化补充 2.0mg/d 叶酸降低对妊娠期间抗癫痫发作药物使用情况的影响,包括总用量、调整频次、调整时机、剂量变化及治疗方案的变动情况相较于妊娠前的变化。 4) 与常规补充 0.4 mg/d 叶酸相比,评价女性癫痫患者孕期强化补充 2.0mg/d 叶酸对癫痫发作的影响。 5)与常规补充 0.4 mg/d 叶酸相比,评价女性癫痫患者孕期强化补充 2.0mg/d 叶酸在不良反应方面的差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Primary Objective:To determine whether high-dose folic acid supplementation (2.0 mg/day) during pregnancy, compared with the standard dose (0.4 mg/day), reduces the risk of a composite outcome comprising preterm birth, small for gestational age, congenital malformations, miscarriage, stillbirth, and neurodevelopmental abnormalities in offspring. 2. Secondary Objectives 1)To compare the effect of high- versus standard-dose folic acid on each component of the composite outcome. 2)To assess the impact on pregnancy complications (gestational hypertension, preeclampsia, placental abruption). 3)To evaluate differences in antiseizure medication use during pregnancy (total dose, adjustment frequency and timing, dose changes, regimen modifications). 4)To assess the effect on seizure frequency during pregnancy. 5)To compare the incidence of adverse events between groups. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.孕前 3 月内出现癫痫发作; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Seizure occurrence within the 3 months prior to conception; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-10 00:00:00至 To 2028-09-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-09-10 00:00:00 至 To 2028-09-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由与研究实施无关的统计人员使用SAS软件产生随机数列。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A randomization sequence will be generated using SAS software by an independent statistician not involved in the study implementation. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲 |
|
Blinding: |
Double blind |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No individual participant data will be shared. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究统一使用电子数据采集与管理系统(EDC)进行数据录入;如不便直接录入者,可先填写病例记录表(CRF),再将数据录入EDC系统以实现统一管理和质控。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The study primarily uses a unified Electronic Data Capture (EDC) system for data entry. When direct entry is not convenient, data can first be recorded on Case Report Forms (CRFs) and then entered into the EDC system for centralized management and quality control. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |